Novo Nordisk Stock Climbs After Hims & Hers Pulls $49 Semaglutide Compound
Novo Nordisk’s Frankfurt-listed shares gained 4.5% on Monday following Hims & Hers’ decision to stop selling a $49 compounded weight-loss pill based on semaglutide after legal warnings from Novo and action from U.S. regulators. The move followed earlier signals from the FDA that it would crack down on unauthorized compounded GLP-1 medications. Desp…